The Bruton's Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Is Active and Tolerated in Relapsed Follicular Lymphoma

被引：23
|
作者：
Fowler, Nathan H. [1 ]
Advani, Ranjana H. [2 ]
Sharman, Jeff [3 ,4 ]
Smith, Sonali M. [5 ]
McGreivy, Jesse [6 ]
Kunkel, Lori [6 ]
Vina Troung [6 ]
Zhou, Cathy [6 ]
Boyd, Thomas E. [7 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Stanford Univ, Stanford, CA 94305 USA
[3] US Oncol Res, Willamette Valley Canc Inst, Eugene, OR USA
[4] US Oncol Res, Res Ctr, Eugene, OR USA
[5] Univ Chicago, Chicago, IL 60637 USA
[6] Pharmacyclics Inc, Sunnyvale, CA USA
[7] N Star Lodge Canc Ctr, Yakima, WA USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.156.156
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
156
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765)
    Burger, Jan A.
    Buggy, Joseph J.
    LEUKEMIA & LYMPHOMA, 2013, 54 (11) : 2385 - 2391
  • [2] Ibrutinib (PCI-32765), the First BTK (Bruton’s Tyrosine Kinase) Inhibitor in Clinical Trials
    Jennifer R. Brown
    Current Hematologic Malignancy Reports, 2013, 8 : 1 - 6
  • [3] Ibrutinib (PCI-32765), the First BTK (Bruton's Tyrosine Kinase) Inhibitor in Clinical Trials
    Brown, Jennifer R.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2013, 8 (01) : 1 - 6
  • [4] PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies
    Winer, Eric S.
    Ingham, Randall R.
    Castillo, Jorge J.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (03) : 355 - 361
  • [5] Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
    Advani, Ranjana H.
    Buggy, Joseph J.
    Sharman, Jeff P.
    Smith, Sonali M.
    Boyd, Thomas E.
    Grant, Barbara
    Kolibaba, Kathryn S.
    Furman, Richard R.
    Rodriguez, Sara
    Chang, Betty Y.
    Sukbuntherng, Juthamas
    Izumi, Raquel
    Hamdy, Ahmed
    Hedrick, Eric
    Fowler, Nathan H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) : 88 - 94
  • [6] A Novel Mutation in Bruton Tyrosine Kinase Confers Acquired Resistance to Ibrutinib (PCI-32765) in CLL
    Furman, R. R.
    Cheng, S.
    Lu, P.
    Setty, M.
    Perez, A.
    Guo, A.
    Racchumi, J.
    Ma, J.
    Coleman, A.
    Venkataraman, K.
    Xu, G.
    Chen, W.
    Chang, B. Y.
    Leslie, C.
    Wang, Y. L.
    MODERN PATHOLOGY, 2014, 27 : 347A - 347A
  • [7] A Novel Mutation in Bruton Tyrosine Kinase Confers Acquired Resistance to Ibrutinib (PCI-32765) in CLL
    Furman, R. R.
    Cheng, S.
    Lu, P.
    Setty, M.
    Perez, A.
    Guo, A.
    Racchumi, J.
    Ma, J.
    Coleman, M.
    Venkataraman, K.
    Xu, G.
    Chen, W.
    Wu, H.
    Chang, B. Y.
    Leslie, C.
    Wang, Y. L.
    LABORATORY INVESTIGATION, 2014, 94 : 347A - 347A
  • [8] A Novel Mutation In Bruton Tyrosine Kinase Confers Acquired Resistance To Ibrutinib (PCI-32765) In CLL
    Furman, Richard R.
    Cheng, Shuhua
    Lu, Pin
    Setty, Menu
    Perez, Alexandar
    Guo, Ailin
    Racchumi, Joelle
    Ma, Jiao
    Coleman, Morton
    Venkataraman, Kabaleeswaran
    Xu, Guozhou
    Chen, Wei
    Wu, Hao
    Chang, Betty Y.
    Leslie, Christina
    Wang, Y. Lynn
    BLOOD, 2013, 122 (21)
  • [9] A clinical trial of the Bruton\#8217;s tyrosine kinase (Btk) inhibitor PCI-32765 in naturally occurring canine lymphoma
    Honigberg, Lee
    Smith, Ashley
    Loury, David
    Buggy, Joseph
    Thamm, Douglas
    CANCER RESEARCH, 2009, 69
  • [10] A Phase I Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Combination with Rituximab (R) and Bendamustine in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)
    Blum, Kristie A.
    Christian, Beth
    Flynn, Joseph M.
    Jaglowski, Samantha M.
    Jones, Jeffrey Alan
    Maddocks, Kami
    Byrd, John C.
    BLOOD, 2012, 120 (21)
12345